April 14, 2015

Taiwan-based drug development company Sunny Pharmtech and Vitruvias Therapeutics, a generic drug development company, on Tuesday announced that they will team up to co-develop a portfolio of generic drug products.

April 7, 2015

The Canadian Generic Pharmaceutical Association on Tuesday established a new Biosimilars Board. 

 

 

March 31, 2015

The director of the FDA’s Office of Generic Drugs temporarily steps down to deal with a medical issue, according to a report by the Regulatory Focus Professionals Society.

March 31, 2015

Teva Pharmaceutical Industries announced the launch of generic Exforge (amlodipine and valsartan) tablets, which are indicated for the treatment of hypertension. 

 

March 27, 2015

The Food and Drug Adminisration on Friday revisited the issue of supplemental applications proposing labeling changes for approved drugs and biologic products. 

March 24, 2015

Actavis last week announced that its acquisition of Allergan has been completed in a transaction valued at $70.5 billion, a deal that creates one of the world’s top 10 pharmaceutical companies by sales revenue, according to the company.

March 24, 2015

Teva Pharmaceutical Industries on Monday announced that Timothy Wright will be heading business development, strategy and innovation for the company, effective April 13. 

March 13, 2015

Colgate announces changes to its board of directors, including the resignation of Joseph Jimenez, CEO of Novartis.

March 10, 2015

The Food and Drug Administration recently published bio-equivalence guidance documents. 

March 10, 2015

Impax Labs completed its acquisition of Tower Holdings (which includes operating subsidiaries CorePharma and Amedra Pharmaceuticals), and Lineage Therapeutics. Impax also announced that it would reshape both the operating and reporting structure of its two divisions.

March 9, 2015

DSN examines chain pharmacy, including in-depth coverage of provider status, kiosks, Medicare and the GPhA elections, in this multi-page report.

March 2, 2015

Mylan on Friday announced the successful completion of the acquisition of Abbott Laboratories' non-U.S. developed markets specialty and branded generics business.

February 27, 2015

GlaxoSmithKline expects to complete its Novartis transaction in the week commencing March 2.

February 26, 2015

Congress introdues legislation to protect FDA user fees from sequestration. 

February 24, 2015

The Food and Drug Administration is looking into enabling holders of abbreviated new drug applications to unilaterally update their generic drug product labels prior to any branded drug change. 

February 18, 2015

Actavis on Wednesday announced that it will adopt a new corporate name — Allergan — following the anticipated, successful completion of the acquisition of Allergan.

February 17, 2015

CVS Health weighs in on the next chapter in the debate about the impact of expensive drugs on the healthcare system in a commentary that appears today on the Health Affairs blog.

February 10, 2015

The Generic Pharmaceutical Association on Monday announced the election of its 2015 executive committee and board of directors.

February 6, 2015

The pharma industry praised outgoing Food and Drug Administration commissioner Margaret Hamburg and welcomed Stephen Ostroff, who will assume the role of acting commissioner.

February 5, 2015

Generic drug prices are going up. Spurred by market opportunities, short-term market exclusivity for some newly launched single-source generics and rising costs for manufacturing, quality control and raw materials, me-too drug manufacturers have escalated a series of price hikes, some of them significant.

February 4, 2015

DSN examines chain pharmacy, including in-depth coverage of telehealth, generic drug prices, and the GPhA CEO to step down, as well as Uhl appointed director of OGD, in this multi-page report.

February 3, 2015

Camber Pharmaceuticals on Tuesday announced the launch of rizatriptan benzoate tablets in 5- and 10-mg dosage strengths. 

 

January 28, 2015

The House Energy and Commerce Committee on Tuesday released a discussion document in the 21st Century Cures initiative.

January 27, 2015

Rep. Jason Chaffetz, R-Utah, last week introduced a bill that would extend to new combination drugs containing molecules already approved by the Food and Drug Administration the same five-year market exclusivity as a drug product containing an entirely new set of active ingredients.